SCHEMBL6074940

SCHEMBL6074940

COC(=O)/C=C/c1ccc(C2=C(c3ccccc3)CCc3ccccc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 7/20 0.47
ESR2 Q92731 4/20 0.47
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
TYR P14679 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
MTNR1A P48039 1/20 0.42
MTNR1B P49286 1/20 0.42
IP6K1 Q92551 1/20 0.42
IP6K3 Q96PC2 1/20 0.42
IP6K2 Q9UHH9 1/20 0.42
HDAC2 Q92769 1/20 0.41
PTPN1 P18031 1/20 0.40
MGLL Q99685 1/20 0.40
BACE1 P56817 1/20 0.39
TTR P02766 1/20 0.39
APP P05067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6074943 1.00 ESR1 (0.47) ESR1ESR2CA12CA1CA2
SCHEMBL14289690 0.93 ESR1 (0.48) ESR1ESR2CA12CA1CA2
SCHEMBL5124386 0.87 ESR1 (0.60) ESR1ESR2CA12CA1CA2
SCHEMBL5116818 0.87 ESR1 (0.60) ESR1ESR2CA12CA1CA2
SCHEMBL14289686 0.85 CA12 (0.46) CA12CA1CA2TYRCA7
SCHEMBL5113727 0.82 ESR1 (0.44) ESR1ESR2MTNR1AMTNR1BHDAC2
SCHEMBL6438313 0.82 ESR1 (0.44) ESR1ESR2MTNR1AMTNR1BHDAC2
SCHEMBL14289691 0.82 ESR1 (0.55) ESR1ESR2CA12CA1CA2
SCHEMBL14320245 0.82 ESR1 (0.55) ESR1ESR2CA12CA1CA2
SCHEMBL14289689 0.81 CA12 (0.44) CA12CA1CA2TYRCA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7323587-B2 Selective estrogen receptor modulators BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-01-29 US disclosed
US-7323587-B2 Selective estrogen receptor modulators BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2008-01-29 US disclosed
US-7045540-B2 Selective estrogen receptor modulators BRISTOL MEYERS SQUIBB COMPANY (US) 2006-05-16 US disclosed
US-20050267183-A1 Selective estrogen receptor modulators KALTENBACH ROBERT F 2005-12-01 US disclosed
US-20050245602-A1 Selective estrogen receptor modulators KALTENBACH ROBERT F 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245602-A1 Selective estrogen receptor modulators ESR1, ESR2, GPER1 ESR1 1/4885ESR2 2/4885CA12 3221/4885
US-20050267183-A1 Selective estrogen receptor modulators ESR2, ESR1, GPER1 ESR1 2/4885ESR2 1/4885CA12 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.